GlassScriptPhysician profile
Franklin Marinelli
NPI 1780676155
$3,937.87
in general payments reported to CMS, 2019-2025
30 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $17.77 · 2021: $259 · 2022: $442 · 2023: $646 · 2024: $776 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,972 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,971.97 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $593.65 | 2019-2025 | |
| Pfizer INC. | $466.35 | 2019-2025 | |
| Gilead Sciences, INC. | $457.18 | 2021-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $445.25 | 2021-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $310.42 | 2019-2025 | Xifaxan |
| Genzyme Corporation | $211.67 | 2023-2025 | |
| Janssen Biotech, INC. | $181.25 | 2019-2025 | Tremfya, Stelara, Simponi |
| Medtronic, INC. | $158.75 | 2023 | Interstim |
| Celgene Corporation | $136.19 | 2022-2024 | Zeposia |
| Alnylam Pharmaceuticals INC. | $133.18 | 2025 | Givlaari |
| Organon LLC | $104.05 | 2024-2025 | Hadlima, Renflexis |
| Intercept Pharmaceuticals, INC. | $98.87 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $87.74 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $72.84 | 2024-2025 | Resmetirom, Rezdiffra |
| Qol Medical, LLC | $59.98 | 2023-2024 | Sucraid, Sucraid |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuraxis, INC. | $58.82 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $50.42 | 2022-2025 | Dupixent |
| Amgen INC. | $37.62 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $29.05 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.02 | 2023 | Cyltezo |
| Nestle Healthcare Nutrition INC. | $26.18 | 2023 | |
| Ardelyx, INC. | $25.35 | 2024 | Ibsrela |
| Daiichi Sankyo INC. | $25.00 | 2022 | |
| Shionogi INC | $22.96 | 2019 | |
| Aimmune Therapeutics, INC. | $21.75 | 2025 | Vowst |
| Ultragenyx Pharmaceutical INC. | $21.47 | 2022 | |
| Ambu INC. | $19.80 | 2021 | |
| Shire North American Group INC | $19.02 | 2019 | |
| Biocon Biologics INC | $18.14 | 2024 | Hulio |
| Orphalan INC | $16.90 | 2025 | Cuvrior |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franklin Marinelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.